Aspen And Mylan Strike A Deal On Australia And New Zealand Portfolio
Executive Summary
Mylan has bolstered its presence in key Australasian markets through a portfolio distribution arrangement with Aspen Pharma, which includes an option to buy in March 2019; the South African firm, on the other hand, is continuing to manage its portfolio in the markets, “allowing enhanced operational focus and removing complexity.”
You may also be interested in...
Mylan launches review to unlock firm’s“true value”
Mylan has put together a board committee which is “actively evaluating a wide range of alternatives to unlock the true value of our one-of-a-kind platform”. Describing current “negative trends and dynamics” in the US as “unsustainable for the US healthcare system”, Mylan insisted investors “under-appreciate and under-value the durability, differentiation and strengths of Mylan’s global diversified business”.
Mylan open to deals to grow OTC offering
Mylan has expressed an interest in acquisitions to grow its burgeoning OTC portfolio, as the firm presses ahead with its goal to reach US$2.0 billion (€1.6 billion) in annual sales by 2021.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.